Edwards Lifesciences Corp 8-K, filed May 4, 2026
Edwards Lifesciences Corp (EW)
8-K
2026-05-04
For: 2026-05-02
View Original
Added on
May 04, 2026
About this 8-K
Edwards Lifesciences Corp filed this 8-K on May 4, 2026, reporting on events of May 2, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 2, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices and zip code)
(949 ) 250-2500
(Registrant's telephone number, including area code)
| N/A | ||
(Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.
Ms. Mistras, age 44, has served as Chief Financial Officer of Viatris, Inc. (NASDAQ: VTRS), a global pharmaceutical and healthcare corporation, since March 1, 2024. Prior to joining Viatris, Inc. as CFO-elect in January 2024, Ms. Mistras was Managing Director, Healthcare Investment Banking at Citigroup Global Markets from September 2019 to December 2023 and prior to that was Managing Director, Healthcare Investment Banking at Goldman Sachs, where she spent over 15 years in their investment banking healthcare group.
In connection with her appointment as Corporate Vice President, Chief Financial Officer, Ms. Mistras and the Company entered into an Offer Letter on May 2, 2026 (the “Offer Letter”). The Offer Letter does not provide for a specified term and provides for an at-will employment relationship.
Pursuant to the Offer Letter, Ms. Mistras will receive a base salary at a rate of $925,000 annually and will be eligible to participate in the Edwards Lifesciences Incentive Plan (the “EIP”) with a target annual bonus amount of not less than 100% of her then current annual base salary rate. Ms. Mistras will also receive a sign-on bonus of $2,013,000 promptly after her start date, and Ms. Mistras has agreed to repay a pro-rata portion of such bonus should she voluntarily terminate her employment, or should the Company terminate her employment for misconduct, within 24 months following her start date.
In addition, the Company will grant Ms. Mistras an award of Company restricted stock units (“RSUs”) with a grant date value of $8,000,000. The RSUs will be scheduled to vest 43.75% on the first anniversary of her start date, 50% on the second anniversary of her start date, and 6.25% on the third anniversary of her start date, with vesting in each case subject to Ms. Mistras’ continued employment with the Company through that date. The RSUs will be granted under the Company’s Long-Term Stock Incentive Compensation Program. Ms. Mistras’ initial RSU award will vest in full should the Company terminate Ms. Mistras’ employment other than for Cause (as defined in the Company’s form of Change-in-Control Severance Agreement (“CIC Agreement”), filed as Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2012), should Ms. Mistras resign from employment with the Company for Good Reason (as defined in the CIC Agreement), or should Ms. Mistras’ employment with the Company terminate due to her death or disability (subject, other than in connection with a termination due to death, to Ms. Mistras providing the Company with a general release of claims).
Ms. Mistras will also be eligible to receive annual equity awards while employed by the Company consistent with the Company’s annual equity awards for its executives generally, with the grant date value of her annual equity award for fiscal year 2026 to be $4,500,000. Ms. Mistras will also be provided with a CIC Agreement and will be entitled to non-change-in-control severance protections under any severance plan applicable to the Company’s Leadership Committee. If Ms. Mistras is entitled to severance benefits under any such severance plan (and not in circumstances covered by the CIC Agreement), her severance benefits will not be less than one times her annual rate of base salary plus one times her target annual EIP bonus amount, a pro-rated EIP bonus for the year in which the termination of employment occurs, and $50,000 in outplacement benefits. Ms. Mistras will also be reimbursed for up to $15,000 of legal fees as well as reimbursement for her costs to relocate from New York, New York to the Orange County, California area.
The foregoing summary of the Offer Letter is qualified in its entirety by the text of the Offer Letter, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
There are no arrangements or understandings between Ms. Mistras and any other persons pursuant to which she was selected as an officer of the Company. There are also no family relationships between Ms. Mistras and any
2
director or executive officer of the Company, and Ms. Mistras does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01. Regulation FD Disclosure.
On May 4, 2026 the Company issued a press release announcing the appointment of Ms. Mistras as the Corporate Vice President, Chief Financial Officer of the Company. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8–K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits | |||||||
| 10.1 | ||||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDWARDS LIFESCIENCES CORPORATION | ||||||||||||||
| By: | /s/ Mark D. Peterson | |||||||||||||
| Mark D. Peterson | ||||||||||||||
Date: May 4, 2026 | Corporate Vice President, General Counsel | |||||||||||||
4
May 1, 2026
Theodora Mistras
New York, NY 10001
Dear Doretta,
On behalf of Edwards Lifesciences LLC, we are pleased to confirm our offer of employment for the position of Chief Financial Officer, reporting to Bernard Zovighian, Chief Executive Officer.
Your start date will be confirmed after successful completion of a preliminary drug screening and background check and if applicable, obtaining authorization to work in the US.
Your bi-weekly salary will be $35,576.92, which is equivalent to $925,000.00 annually. Additionally, you will be eligible to participate in the Edwards Lifesciences Incentive Plan (EIP) for the current calendar year (and each calendar year thereafter), at a target bonus of not less than 100% of your then current base salary – (currently, $925,000.00). (Your EIP payment for the 2026 calendar year will be based on your eligible earnings for the portion of the year worked. If hired within the last three months of the year, you will be included in the EIP plan for the following calendar year.)
You will receive a sign-on bonus of $2,013,000.00 (gross) to be paid through the first available payroll cycle following your start date. Important details related to your sign-on bonus are outlined in the accompanying Sign-On Bonus Agreement.
Your offer also includes a recommendation for a new hire restricted stock unit (RSU) grant valued at $8,000,000.00. The RSU grant will vest 43.75% on the 1st anniversary of your start date, an additional 50% on the 2nd anniversary of your start date, and the final 6.25% on the 3rd anniversary of your start date. The new hire RSU grant is subject to approval by the Compensation and Governance Committee of the Board of Directors (the “Compensation Committee”). This approval is expected to occur prior to your start date at the next regularly scheduled Board of Directors (the “Board”) meeting, and this new hire RSU grant is expected to be granted at the next regularly scheduled Board meeting following your start date. The value of the restricted stock units is based on the closing price of the common stock on the grant date. The restricted stock units will be granted under and be subject to the terms of the Edwards Lifesciences Long-Term Stock Incentive Compensation Program (as amended from time to time) and the form grant agreements thereunder. The new hire RSU grant is subject to accelerated vesting, in full, in the event of (i) (x) an involuntary termination of your employment by Edwards not for Cause, (y) you are terminated by Edwards following Disability or (z) you resign for Good Reason (as such terms are defined in the Edwards Lifesciences Corporation Change-in-Control Severance Agreement (“CIC Agreement”)) that is not related to change-in-control, and, as it relates to (i)(x), (i)(y) and (i)(z), subject to you timely providing a general release of claims, or (ii) your employment terminates on account of your death.
You will receive an annual equity grant for fiscal year 2026 valued at $4,500,000.00 that will be a combination of stock options, performance based restricted stock units, and restricted stock units, subject to approval by the Compensation Committee prior to your start date. This annual equity grant is expected to be granted at the next regularly scheduled Board meeting following your start date. The awards will be subject to vesting and other terms set forth in the applicable award agreement(s), which will be no less favorable than the award terms applicable to other executives. Commencing for fiscal year 2027 and each fiscal year thereafter, you will be eligible to receive an annual equity grant in line with the Company’s pay for performance philosophy and which awards will be subject to vesting and other terms set forth in the applicable award agreement(s), which will be no less favorable than the terms of the Company’s annual executive equity awards generally available to other executives.
You will be covered by a severance pay plan applicable to the Leadership Committee (“Severance Plan”), and you will be provided with a CIC Agreement. Both arrangements provide participants with severance benefits for certain qualifying terminations of employment. Your severance benefits under the Severance Plan for a qualifying termination not in connection with or following a change-in-control of Edwards will not be less than the total severance pay of one times your annual base salary plus one times your annual bonus target, a pro-rated bonus for the year in which the termination occurs, and certain benefits including $50,000 outplacement services. Severance benefits under the CIC Agreement are available for qualifying terminations of employment in connection with or following a change in control of Edwards, and equal to two times your annual base salary and annual bonus amount (calculated as the greater of your target annual bonus for the year of termination or the annual bonus actually earned for the year before the year of termination), a pro-rated bonus for the year in which the event occurs, accelerated vesting of outstanding and unvested long-term incentive awards, plus certain other benefits (including continued participation in our medical and dental plans for three years
following termination of employment). Your participation in these arrangements is subject to the terms of the applicable plan or agreement, including applicable release requirements and our ability to amend or terminate the arrangement in accordance with its terms.
Edwards will provide you with Relocation benefits for your move from your primary residence in New York, NY to the Orange County, California area. Important details related to your relocation are outlined in the accompanying Relocation Benefits Agreement.
The Company will reimburse you for your legal fees up to $15,000 that you incur in connection with the review and negotiation of the terms of this offer letter, which reimbursement will be provided to you within 30 days following the receipt by the Company of the invoice from your legal counsel.
You will be eligible to participate in the Edwards Lifesciences Employee Benefits Program. Information on the details of eligibility and participation will be sent to you from our Benefits Administrator, TRI-AD, via email to your Edwards email address. If you do not receive an email from TRI-AD within 2 weeks from your start date, please contact the Edwards Benefits Center at 1-800-955-1237. Please note that your benefits will be effective on the first day of employment, provided you complete your enrollment within 30 days from your hire date. If you do not enroll by your deadline, you will not be able to enroll until the next Open Enrollment period, which occurs in May of each year with changes effective July 1.
Because we value your well-being, you will accrue 25 days of vacation per year.
Note that all forms of compensation are subject to applicable withholdings and deductions.
Conditions of Employment:
•Prior Employment Agreements: Your employment offer is contingent upon the absence of any agreements, obligations, or restrictions (whether contractual, legal, or otherwise) arising from prior employment that may affect your ability to be employed by Edwards or limit the manner in which you may be employed.
•No Third-Party Information: Edwards is committed to ethical conduct in the marketplace. In particular, we aim to preserve the highest standard of confidentiality and intellectual property protection. In signing this offer and your employment agreement, you agree that Edwards has made you aware of this commitment, and you undertake to refrain from sharing with any representative of Edwards any third-party confidential information or intellectual property, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information. You also represent that you have not retained any confidential information, documents, materials, or any product samples belonging to any former employer.
•Drug Screening: Your employment offer is contingent upon completing your drug test within 48 hours of your receipt of your Drug-Screen Registration Instructions and upon satisfactory drug screening results consistent with company policy. Drug screening results must be obtained before your start date. Additional information regarding your drug screen will be provided via email.
•Background Checking: Your employment is contingent upon the results of a background check that will be conducted by Edwards Lifesciences or on behalf of Edwards Lifesciences.
•Authorization to Work: In order to comply with federal regulations relative to authorization to work (Immigration Reform Act of 1986), you will be required to present forms of documentation which establish your eligibility to work in the United States. Please complete Section I of the Form I-9 available through your onboarding portal and bring it with you on your first day of employment with either: one document from List A; or two documents - one from List B and one from List C. Documents presented must be originals.
•Non-Debarment, Suspension or Exclusion: This offer of employment is conditioned upon the verification that you are not: (i) currently debarred, suspended, excluded or otherwise ineligible to participate in any federal or state healthcare program; or (ii) currently under investigation or involved in any proceeding that might result in your debarment, suspension, exclusion or ineligibility to participate in any federal or state healthcare program. Edwards will not employ or contract with any individual who is debarred, suspended, excluded or otherwise ineligible to participate in any federal program.
•Visa Status: In the event you need visa sponsorship from Edwards, your employment offer is contingent
upon you lawfully maintaining your current immigration status.
upon you lawfully maintaining your current immigration status.
•Company Policy: By accepting this offer and, in commencing employment with Edwards, you agree to comply with all applicable Edwards policies, as such policies are in effect from time to time during your employment.
Your start date may be postponed if there is a significant delay in the receipt of your background or drug screening results and, if applicable, upon obtaining authorization to work in the US. Please sign and submit your documents electronically. You will receive additional instruction on the completion of new hire forms through your onboarding process. For any questions, please contact me.
This offer, if accepted, creates an employment-at-will relationship between you and Edwards Lifesciences and may be terminated at any time by you or Edwards Lifesciences. It is not intended, nor should it be construed, as a contract of continued employment. This employment offer is also subject to your compliance with the requirement to complete all requested New Hire Forms. Please review them carefully and call me if you need further clarification prior to your start date.
Doretta, we are confident that you will make a significant contribution to Edwards Lifesciences. If you have any questions, please contact me.
Best regards,
/s/ Christine McCauley
Christine McCauley
CVP, Human Resources
cc: HRBP
Employee File
___________________________________________________________________
OFFER ACCEPTED:
__/s/ Theodora Mistras_______________________
____May 2, 2026____________________________
Date Signed
SIGN-ON BONUS AGREEMENT
I.Edwards Lifesciences LLC (the “Company”) has offered to provide you with a sign-on bonus. This sign-on bonus is being offered to you as a discretionary monetary payment at the outset of employment and is not tied to your job performance.
II.You will receive a sign-on bonus of $2,013,000.00 (gross) to be paid through the first available payroll cycle following your start date. This payment will be subject to all applicable taxes and withholdings. If your employment with the Company is terminated voluntarily by you or by the Company due to your misconduct prior to two (2) years of employment, the bonus will be repayable to the Company on a prorated basis within one year of your termination date. For example, should your termination occur after twelve (12) months of employment, the pro-rated amount due would be calculated as follows [(24-12/24]*($2,013,000.00) = $1,006,500.00.
III.You have the right to consult an attorney regarding this Sign-On Bonus Agreement and are provided with five (5) business days to obtain the advice of counsel prior to agreeing to this Agreement.
IV.Additionally, you have the option of deferring payment of the sign-on bonus until completion of twenty-four (24) months of employment.
V.You understand that nothing in this Agreement is intended to create a right of employment for any specified term or otherwise change or affect the terms of your employment with the Company except as explicitly described in this Agreement.
VI.It is the intent of the Company to comply with the provisions of California Business & Professions Code section 16608 and California Labor Code section 926. If any provision of this Agreement is held to be invalid, unenforceable, or void, that provision shall be severed and the remainder shall remain in full force and effect. In any legal action or other proceeding brought to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to recover reasonable attorneys’ fees and costs related to the matter.
Accepted and Agreed:
Signature: /s/ Theodora Mistras
Date: May 2, 2026
Sign-On Bonus Agreement
EXHIBIT 99.1
 | Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · Fax: 949.250.2525 www.edwards.com | ||||
FOR IMMEDIATE RELEASE
Media: Amy Meshulam, media@edwards.com
Investors: Gerianne Sarte, investor_relations@edwards.com
EDWARDS LIFESCIENCES ANNOUNCES APPOINTMENT OF CFO
IRVINE, Calif., May 4, 2026 – Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company’s corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role.
Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company’s global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor’s degree in international studies from the University of Pennsylvania and a bachelor’s degree in economics from the Wharton School.
“We are very pleased to welcome Doretta to Edwards as our next CFO,” said Bernard Zovighian, Edwards’ CEO. “Doretta’s broad experience will be instrumental as we execute our differentiated strategy. We look forward to her leadership as we continue to invest in innovation, and also deliver distinguished and durable financial results and long-term value to patients, customers, shareholders and the broader healthcare ecosystem.”
Ullem has served as Edwards’ CFO since 2014. “We would like to once again thank Scott for his outstanding leadership, partnership and impact,” Zovighian added. “His commitment to a thoughtful transition and his continued support as a strategic advisor in the months ahead
reflects the discipline and continuity that have long defined Edwards’ approach to leadership. We are grateful for Scott’s numerous contributions over the years that have helped to strengthen our company both strategically and financially.”
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian regarding Mistras’ experience being instrumental to the Edwards strategy to deliver long-term value to our stakeholders, the commencement of Mistras’ appointment in May 2026 and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, and the stylized E logo, are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
# # #